Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 312

1.

Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.

Coffey G, DeGuzman F, Inagaki M, Pak Y, Delaney SM, Ives D, Betz A, Jia ZJ, Pandey A, Baker D, Hollenbach SJ, Phillips DR, Sinha U.

J Pharmacol Exp Ther. 2012 Feb;340(2):350-9. doi: 10.1124/jpet.111.188441. Epub 2011 Oct 31.

2.

The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.

Spurgeon SE, Coffey G, Fletcher LB, Burke R, Tyner JW, Druker BJ, Betz A, DeGuzman F, Pak Y, Baker D, Pandey A, Hollenbach SJ, Sinha U, Loriaux MM.

J Pharmacol Exp Ther. 2013 Feb;344(2):378-87. doi: 10.1124/jpet.112.200832. Epub 2012 Dec 7.

3.

Selective spleen tyrosine kinase inhibition delays autoimmune arthritis in mice.

Zhang Z, Cao C, Sun S, Xu Q.

Mol Med Rep. 2015 Aug;12(2):2902-6. doi: 10.3892/mmr.2015.3759. Epub 2015 May 8.

PMID:
25955571
4.

Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.

Liao C, Hsu J, Kim Y, Hu DQ, Xu D, Zhang J, Pashine A, Menke J, Whittard T, Romero N, Truitt T, Slade M, Lukacs C, Hermann J, Zhou M, Lucas M, Narula S, DeMartino J, Tan SL.

Arthritis Res Ther. 2013 Oct 4;15(5):R146. doi: 10.1186/ar4329.

5.

Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.

Hoellenriegel J, Coffey GP, Sinha U, Pandey A, Sivina M, Ferrajoli A, Ravandi F, Wierda WG, O'Brien S, Keating MJ, Burger JA.

Leukemia. 2012 Jul;26(7):1576-83. doi: 10.1038/leu.2012.24. Epub 2012 Feb 7.

6.

R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.

Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, Masuda ES.

J Pharmacol Exp Ther. 2006 Dec;319(3):998-1008. Epub 2006 Aug 31. Erratum in: J Pharmacol Exp Ther. 2013 May;345(2):326.

7.

Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice.

Llop-Guevara A, Porras M, Cendón C, Di Ceglie I, Siracusa F, Madarena F, Rinotas V, Gómez L, van Lent PL, Douni E, Chang HD, Kamradt T, Román J.

Arthritis Res Ther. 2015 Dec 10;17:356. doi: 10.1186/s13075-015-0866-0.

8.

Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells.

Wossning T, Herzog S, Köhler F, Meixlsperger S, Kulathu Y, Mittler G, Abe A, Fuchs U, Borkhardt A, Jumaa H.

J Exp Med. 2006 Dec 25;203(13):2829-40. Epub 2006 Nov 27.

9.

A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation.

Ferguson GD, Delgado M, Plantevin-Krenitsky V, Jensen-Pergakes K, Bates RJ, Torres S, Celeridad M, Brown H, Burnett K, Nadolny L, Tehrani L, Packard G, Pagarigan B, Haelewyn J, Nguyen T, Xu L, Tang Y, Hickman M, Baculi F, Pierce S, Miyazawa K, Jackson P, Chamberlain P, LeBrun L, Xie W, Bennett B, Blease K.

PLoS One. 2016 Jan 12;11(1):e0145705. doi: 10.1371/journal.pone.0145705. eCollection 2016.

10.

A novel inhaled Syk inhibitor blocks mast cell degranulation and early asthmatic response.

Ramis I, Otal R, Carreño C, Domènech A, Eichhorn P, Orellana A, Maldonado M, De Alba J, Prats N, Fernández JC, Vidal B, Miralpeix M.

Pharmacol Res. 2015 Sep;99:116-24. doi: 10.1016/j.phrs.2015.05.011. Epub 2015 Jun 4.

PMID:
26051661
11.

Critical role for Syk in responses to vascular injury.

Andre P, Morooka T, Sim D, Abe K, Lowell C, Nanda N, Delaney S, Siu G, Yan Y, Hollenbach S, Pandey A, Gao H, Wang Y, Nakajima K, Parikh SA, Shi C, Phillips D, Owen W, Sinha U, Simon DI.

Blood. 2011 Nov 3;118(18):5000-10. doi: 10.1182/blood-2011-06-360743. Epub 2011 Aug 31.

12.

The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.

Coffey G, Betz A, DeGuzman F, Pak Y, Inagaki M, Baker DC, Hollenbach SJ, Pandey A, Sinha U.

J Pharmacol Exp Ther. 2014 Dec;351(3):538-48. doi: 10.1124/jpet.114.218164. Epub 2014 Sep 24.

13.

Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors.

Hirabayashi A, Mukaiyama H, Kobayashi H, Shiohara H, Nakayama S, Ozawa M, Tsuji E, Miyazawa K, Misawa K, Ohnota H, Isaji M.

Bioorg Med Chem. 2008 Oct 15;16(20):9247-60. doi: 10.1016/j.bmc.2008.09.015. Epub 2008 Sep 9.

PMID:
18823784
14.

Comparison of the anti-allergic activity of Syk inhibitors with optimized Syk siRNAs in FcepsilonRI-activated RBL-2H3 basophilic cells.

Sanderson MP, Gelling SJ, Rippmann JF, Schnapp A.

Cell Immunol. 2010;262(1):28-34. doi: 10.1016/j.cellimm.2009.12.004. Epub 2009 Dec 14.

PMID:
20053395
15.

Inhibition of spleen tyrosine kinase attenuates allergen-mediated airway constriction.

Moy LY, Jia Y, Caniga M, Lieber G, Gil M, Fernandez X, Sirkowski E, Miller R, Alexander JP, Lee HH, Shin JD, Ellis JM, Chen H, Wilhelm A, Yu H, Vincent S, Chapman RW, Kelly N, Hickey E, Abraham WM, Northrup A, Miller T, Houshyar H, Crackower MA.

Am J Respir Cell Mol Biol. 2013 Dec;49(6):1085-92. doi: 10.1165/rcmb.2013-0200OC.

PMID:
23889698
16.

Inhibition of spleen tyrosine kinase as treatment of postoperative ileus.

van Bree SH, Gomez-Pinilla PJ, van de Bovenkamp FS, Di Giovangiulio M, Farro G, Nemethova A, Cailotto C, de Jonge WJ, Lee K, Ramirez-Molina C, Lugo D, Skynner MJ, Boeckxstaens GE, Matteoli G.

Gut. 2013 Nov;62(11):1581-90. doi: 10.1136/gutjnl-2012-302615. Epub 2012 Dec 13.

PMID:
23242119
17.

Identification of the Syk kinase inhibitor R112 by a human mast cell screen.

Rossi AB, Herlaar E, Braselmann S, Huynh S, Taylor V, Frances R, Issakani SD, Argade A, Singh R, Payan DG, Masuda ES.

J Allergy Clin Immunol. 2006 Sep;118(3):749-55. Epub 2006 Jul 28.

PMID:
16950297
18.
19.

Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia.

Chen Z, Shojaee S, Buchner M, Geng H, Lee JW, Klemm L, Titz B, Graeber TG, Park E, Tan YX, Satterthwaite A, Paietta E, Hunger SP, Willman CL, Melnick A, Loh ML, Jung JU, Coligan JE, Bolland S, Mak TW, Limnander A, Jumaa H, Reth M, Weiss A, Lowell CA, Müschen M.

Nature. 2015 May 21;521(7552):357-61. doi: 10.1038/nature14231. Epub 2015 Mar 23. Erratum in: Nature. 2016 Jun 2;534(7605):138.

20.

The BAFF receptor transduces survival signals by co-opting the B cell receptor signaling pathway.

Schweighoffer E, Vanes L, Nys J, Cantrell D, McCleary S, Smithers N, Tybulewicz VL.

Immunity. 2013 Mar 21;38(3):475-88. doi: 10.1016/j.immuni.2012.11.015. Epub 2013 Feb 28.

Supplemental Content

Support Center